Insights
Insights From Our Experts
Articles
News Alert: MCIT Program Delayed Until December
The Centers for Medicare and Medicaid Services (CMS) again delayed implementation of the Medicare Coverage of Innovative Technology (MCIT) program, now until December 15, 2021. The program, as described in the current and preceding rules, will…
Gross-To-Net: Challenges and Best Practices
The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization and underutilization. Moving forward, the more diligent payers…
Pharma’s Push and Pull: Products Approved Amid Government Pushes for Regulation and Pricing Change: April 2021
Global healthcare and life sciences innovation continues to surge at an unprecedented rate, and government entities worldwide are trying to keep up. Price transparency and treatment affordability remain at the top of the list for legislative concern. For instance, United States…
The Secret’s Out: The Impact of Net Price Transparency
Pricing system pressures are increasing for the top four markets in Europe. Price transparency, changes to public health plans and curative therapies are set to disrupt traditional drug pricing. To navigate this ever-shifting landscape, companies must…
Audit From Anywhere: Upgrade Your Quality System Audit Programs
As the world strives every day to adapt to changes this year, one change that pharma manufacturers are adapting to is the impact of COVID-19 on product safety audits. From supplier audits to evaluating internal or affiliated sites with…
Are You Tracking the Performance and Satisfaction Ratings of Your Patient Services?
The types of services patients need for support change and fluctuate over time, particularly as a product moves through its lifecycle. The patient services necessary to drive access, affordability and adherence to your product in the…
Learning How to Play Dilution Dodgeball
The healthcare industry is reaching new heights in innovation, and as new drugs are founded, owners of biotech companies must decide whether or not they want to independently bring their product to market. Developing and successfully commercializing a…
Visualizing EVERSANA’s Omnichannel Activation Model
The pharma industry’s needs have evolved beyond one-dimensional playbooks, disconnected promotional efforts and limited ability to assess stakeholder engagement. Manufacturers need to adopt an omnichannel model that goes beyond “marketing” to provide actionable insights that better…
Pharmaceutical Opportunities and Challenges Facing Long-Term Care Facilities
Posted by
Dr. Richard Stefanacci on April 27, 20214/27/21
Skilled nursing facilities (SNF) and long-term care (LTC) facilities have been a major source for news stories throughout the COVID-19 pandemic due to the devastation brought to patient populations. Now, pharmaceutical manufacturers have an opportunity to…
Ask the Expert: How to Maximize Your Omnichannel Strategy
Omnichannel strategies are transforming the way consumers interact with brands across industries – from the all-in-one Magic Band experience at Disney to buying your favorite latte with the Starbucks app. The pharmaceutical industry is no exception,…